A meta-analysis of the antiviral activity of the HBV-specific immunotherapeutic TG1050 confirms its value over a wide range of HBsAg levels in a persistent HBV pre-clinical model

• Hoofdauteurs: Roland Kratzer (Auteur), Benoît Sansas (Auteur), Karine Lélu (Auteur), Alexei Evlachev (Auteur), Doris Schmitt (Auteur), Nathalie Silvestre (Auteur), Geneviève Inchauspé (Auteur), Perrine Martin (Auteur)
• Formaat: Boek
• Gepubliceerd in: Taylor & Francis Group, 2018-06-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Pre-clinical models mimicking persistent hepatitis B virus (HBV) expression are seldom, do not capture all features of a human chronic infection and due to their complexity, are subject to variability. We report a meta-analysis of seven experiments performed with TG1050, an HBV-targeted immunotherap...